Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

1.

The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Pain Med. 2011 May;12(5):697-705. doi: 10.1111/j.1526-4637.2011.01096.x. Epub 2011 Apr 11.

PMID:
21481164
2.

Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea.

Smith WR, Bauserman RL, Ballas SK, McCarthy WF, Steinberg MH, Swerdlow PS, Waclawiw MA, Barton BA; Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Pain. 2009 Nov;146(1-2):91-8. doi: 10.1016/j.pain.2009.07.008. Epub 2009 Aug 14.

PMID:
19683393
3.

Overview of non-small cell lung cancer.

Flood WA.

Manag Care. 2005 Feb;14(2 Suppl):4-8. Review. No abstract available.

4.
5.

Esophageal cancer.

Flood WA, Forastiere AA.

Cancer Treat Res. 1998;98:1-40. Review. No abstract available.

PMID:
10326663
6.

Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.

Rowinsky EK, Flood WA, Sartorius SE, Bowling KM, Ettinger DS.

Invest New Drugs. 1997;15(2):129-38.

PMID:
9220292
7.

Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.

Rowinsky EK, Flood WA, Sartorius SE, Bowling MK, Wagner J, Ettinger DS.

Semin Oncol. 1995 Aug;22(4 Suppl 9):48-54.

PMID:
7644928
8.

Esophageal cancer.

Flood WA, Forastiere AA.

Curr Opin Oncol. 1995 Jul;7(4):381-6. Review.

PMID:
7578389
9.

Transformation of NIH 3T3 cells by cotransfection with c-src and nuclear oncogenes.

Shalloway D, Johnson PJ, Freed EO, Coulter D, Flood WA Jr.

Mol Cell Biol. 1987 Oct;7(10):3582-90.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk